Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Novel direct-acting anticoagulants for risk reduction in ACS.

Dobesh PP, Oestreich JH.

J Pharm Pract. 2013 Aug;26(4):358-66. doi: 10.1177/0897190012465954. Epub 2012 Nov 19.

PMID:
23172897
2.

Novel oral anticoagulants in acute coronary syndrome.

Costopoulos C, Niespialowska-Steuden M, Kukreja N, Gorog DA.

Int J Cardiol. 2013 Sep 10;167(6):2449-55. doi: 10.1016/j.ijcard.2012.08.014. Epub 2012 Sep 16. Review.

PMID:
22989603
3.

Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.

Weitz JI.

Thromb Haemost. 2014 Nov;112(5):924-31. doi: 10.1160/TH14-03-0265. Epub 2014 Jul 17. Review.

PMID:
25030773
4.

Rivaroxaban in acute coronary syndromes--is it prime time?

Asrar ul Haq M, van Gaal WJ.

Expert Rev Cardiovasc Ther. 2014 Jun;12(6):649-58. doi: 10.1586/14779072.2014.910118. Epub 2014 Apr 19. Review.

PMID:
24746010
5.

Potential role of rivaroxaban in patients with acute coronary syndrome.

Fitchett DH.

Drug Des Devel Ther. 2012;6:349-57. doi: 10.2147/DDDT.S30342. Epub 2012 Nov 22. Review.

6.

The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.

Cohen M, Iyer D.

Cardiovasc Ther. 2014 Oct;32(5):224-32. doi: 10.1111/1755-5922.12083. Review.

7.

Improving long-term ACS management: is there a role for the new antiplatelets?

Cohen M.

J Interv Cardiol. 2012 Oct;25(5):425-32. doi: 10.1111/j.1540-8183.2012.00738.x. Epub 2012 May 11. Review.

PMID:
22574644
8.

Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.

Ganetsky VS, Hadley DE, Thomas TF.

Pharmacotherapy. 2014 Jun;34(6):590-604. doi: 10.1002/phar.1375. Epub 2013 Dec 13. Review.

PMID:
24338703
9.

New antithrombotics for secondary prevention of acute coronary syndrome.

Goto S, Tomita A.

Clin Cardiol. 2014 Mar;37(3):178-87. doi: 10.1002/clc.22233. Epub 2014 Jan 22. Review.

10.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
11.

Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.

Bassand JP.

EuroIntervention. 2014 Mar 20;9(11):1333-41. doi: 10.4244/EIJV9I11A224. Review.

12.

New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.

Oldgren J, Wallentin L, Alexander JH, James S, Jönelid B, Steg G, Sundström J.

Eur Heart J. 2013 Jun;34(22):1670-80. doi: 10.1093/eurheartj/eht049. Epub 2013 Mar 6. Review.

13.

NOAC in acute coronary syndrome and AF?

Niespialowska-Steuden M, Collins P, Costopoulos C, Gorog DA.

Cardiovasc Hematol Disord Drug Targets. 2014;14(2):154-64. Review. Erratum in: Cardiovasc Hematol Disord Drug Targets. 2015;15(1):85.

PMID:
24993123
14.

[Contribution of the new oral anticoagulants to the treatment of acute coronary syndrome].

Fernández D, Penela D, Heras M.

Med Clin (Barc). 2012 Oct;139 Suppl 2:41-5. doi: 10.1016/S0025-7753(12)70041-6. Review. Spanish.

PMID:
23498072
15.

Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials.

Komócsi A, Vorobcsuk A, Kehl D, Aradi D.

Arch Intern Med. 2012 Nov 12;172(20):1537-45. doi: 10.1001/archinternmed.2012.4026. Review.

PMID:
23007264
16.

Novel oral anticoagulants in the treatment of acute coronary syndromes: is there any room for new anticoagulants?

Deftereos S, Bouras G, Giannopoulos G, Kossyvakis C, Panagopoulou V, Pyrgakis V, Stefanadis C.

Curr Clin Pharmacol. 2012 Aug;7(3):195-208. Review.

PMID:
22564121
17.

Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.

Kar S, Bhatt DL.

Coron Artery Dis. 2012 Sep;23(6):380-90. doi: 10.1097/MCA.0b013e328356490a. Review.

PMID:
22728913
18.

Rivaroxaban for the treatment of acute coronary syndromes.

Wong CK, White HD.

Expert Opin Pharmacother. 2013 May;14(7):917-27. doi: 10.1517/14656566.2013.780029. Epub 2013 Apr 2. Review.

PMID:
23544968
19.

Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.

Turpie AG.

Expert Rev Cardiovasc Ther. 2014 Aug;12(8):963-76. doi: 10.1586/14779072.2014.938055. Epub 2014 Jul 12. Review.

PMID:
25017622
20.

Safety of new oral anticoagulants with dual antiplatelet therapy in patients with acute coronary syndromes.

Tsu LV, Dager WE.

Ann Pharmacother. 2013 Apr;47(4):573-7. doi: 10.1345/aph.1R576. Epub 2013 Apr 2. Review.

PMID:
23548645

Supplemental Content

Support Center